[6]Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan;5(...
[2]Giuseppe Curigliano, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therap...
有研究表明,HER2低表达的临床病理学特征与HER2 0和HER2阳性均存在显著差异[3],在疾病分级方面:HER2低表达乳腺癌的组织学分级2级比HER2 0和HER2阳性更常见,分别为59.3%vs.34.4%vs.39.6%;在分子分型分布方面:与HER2 0表达存在差异,Lum...
[3]Sanford RA, Song J, Gutierrez-Barrera AM, et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors[J]. Cancer, 2015, 121(19):3422-3427. [4]Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Rec...
[2]Burstein HJ.The distinctive nature of HER2-positive breast cancers.N Engl J Med.2005;353:1652–4. [3]Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science.1987;235:177–82. ...
In a nontumorous group of 102 specimens, 5 were HER2-positive (4.9%) (18.6% vs. 4.9%, p < 0.01), and 2 were HER3-positive (2.0%) (13.7% vs. 2.0%, p < 0.01 No co-overexpression of HER2 and HER3 was observed. The intestinal type of GC exhibited a higher rate of HER2 ...
[3]Sanford RA, Song J, Gutierrez-Barrera AM, et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors[J]. Cancer, 2015, 121(19):3422-3427. [4]Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Rec...
[7] National Institutes of Health. U.S. National Library of Medicine. ClinicalTrials. gov. Chemotherapy and lapatinib or trastuzumab in treating women with HER2/Neu-positive metastatic breast cancer. 2022. https://clinicaltrials.gov/ct2/show/results/NCT00667251. [Accessed 16 March 2022]. ...
phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. Snehal S Patel, David B McWilliams, Marisa S Patel, Christine T Fischette, Jaye Thompson and F Joseph Da...
[3]Kang Z, Jin Y, Yu H,et al. Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis. BMC Cancer. 2024 Jun 8;24(1):708. 审批编号：CN-147873 有效期至：2025-11-21本材料...